X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two Massachusetts-based companies, with X4 Pharmaceuticals specializing in immune cell trafficking therapies for conditions such as primary immunodeficiencies and cancer, and Arsanis leading the charge in monoclonal antibody (mAb) immunotherapies for […]